ROCKVILLE, Md., May 29, 2018 /PRNewswire/ -- CASI
Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company
dedicated to the development and delivery of high quality,
cost-effective pharmaceutical products and innovative therapeutics
to patients in the U.S., China and
throughout the world, announces it will present at the BIO
International Convention, June 4-7,
2018 in Boston, MA.
Presentation details are below:
Event: BIO International Convention
Date: Monday, June 4, 2018
Time: 3:30 P.M.
Presenter: James E. Goldschmidt Ph.D., Senior Vice President,
Business Development
Presentation Room: Theater 4
A copy of the presentation materials will be made available
directly through the Investor Relations section of the company's
website, www.casipharmaceuticals.com, following the
presentation.
About CASI Pharmaceuticals, Inc.
CASI Pharmaceuticals (NASDAQ: CASI) is a biopharmaceutical
company dedicated to the development and delivery of high quality,
cost-effective pharmaceutical products and innovative therapeutics
to patients in the U.S., China and
throughout the world. CASI's product pipeline features three U.S.
Food and Drug Administration (FDA)-approved drugs in-licensed from
Spectrum Pharmaceuticals, Inc. for China regional rights. These are currently in
various stages in the regulatory process for market approval in
China. The Company also acquired a
portfolio of 25 FDA-approved abbreviated new drug applications
(ANDAs), and four pipeline ANDAs that are pending FDA approval.
CASI is headquartered in Rockville,
Maryland and has a wholly owned subsidiary and R&D
operations in Beijing, China. More
information on CASI is available
at www.casipharmaceuticals.com.
Forward Looking Statements
This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act with
respect to the outlook for expectations for future financial or
business performance, strategies, expectations and goals.
Forward-looking statements are subject to numerous assumptions,
risks and uncertainties, which change over time. Forward-looking
statements speak only as of the date they are made, and no duty to
update forward-looking statements is assumed. Actual results
could differ materially from those currently anticipated due to a
number of factors, including: the risk that we may be unable to
continue as a going concern as a result of our inability to raise
sufficient capital for our operational needs; the possibility that
we may be delisted from trading on the Nasdaq Capital Market; the
volatility in the market price of our common stock; risks relating
to interests of our largest stockholders that differ from our other
stockholders; the risk of substantial dilution of existing
stockholders in future stock issuances, the difficulty of executing
our business strategy in China;
the risk that we will not be able to effectively select, register
and commercialize products from our recently acquired portfolio of
ANDAs; our inability to predict when or if our product candidates
will be approved for marketing by CFDA authorities; our inability
to enter into strategic partnerships for the development,
commercialization, manufacturing and distribution of our proposed
product candidates or future candidates; risks relating to the need
for additional capital and the uncertainty of securing additional
funding on favorable terms; risks associated with our product
candidates; risks associated with any early-stage products under
development; the risk that results in preclinical and early
clinical models are not necessarily indicative of later clinical
results; uncertainties relating to preclinical and clinical trials,
including delays to the commencement of such trials; the lack of
success in the clinical development of any of our products;
dependence on third parties; and risks relating to the
commercialization, if any, of our proposed products (such as
marketing, safety, regulatory, patent, product liability, supply,
competition and other risks). Such factors, among others,
could have a material adverse effect upon our business, results of
operations and financial condition. We caution readers not to
place undue reliance on any forward-looking statements, which only
speak as of the date made. Additional information about the factors
and risks that could affect our business, financial condition and
results of operations, are contained in our filings with the U.S.
Securities and Exchange Commission, which are available at
www.sec.gov.
EVOMELA®, MARQIBO®, and
ZEVALIN® are proprietary to Spectrum
Pharmaceuticals, Inc. and its affiliates.
COMPANY
CONTACT:
CASI Pharmaceuticals,
Inc.
240.864.2643
ir@casipharmaceuticals.com
|
INVESTOR
CONTACT:
Solebury
Trout
Jennifer
Porcelli
646.378.2962
jporcelli@troutgroup.com
Brennan
Doyle
617.221.9005
BDoyle@troutgroup.com
|
MEDIA
CONTACT:
PressComm PR,
LLC
Jamie
Lacey-Moreira
410.299.3310
jamielacey@presscommpr.com
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/casi-pharmaceuticals-to-present-at-the-bio-international-convention-300655212.html
SOURCE CASI Pharmaceuticals, Inc.